|
| 36639200 | Single-cell profiling of multiple myeloma reveals molecular response to FGFR3 inhibitor despite clinical progression. | Cold Spring Harb Mol Case Stud | 2023 |
| 32665698 | The mevalonate pathway is an actionable vulnerability of t(4;14)-positive multiple myeloma. | Leukemia | 2021 |
| 33509009 | A phase-1 trial of linsitinib (OSI-906) in combination with bortezomib and dexamethasone for the treatment of relapsed/refractory multiple myeloma. | Leuk Lymphoma | 2021 |
| 34732728 | Longitudinal single-cell analysis of a myeloma mouse model identifies subclonal molecular programs associated with progression. | Nat Commun | 2021 |
| 28492226 | Circulating tumour DNA sequence analysis as an alternative to multiple myeloma bone marrow aspirates. | Nat Commun | 2017 |
| 25311528 | Differential regulation of FGFR3 by PTPN1 and PTPN2. | Proteomics | 2015 |
| 26158521 | FV-162 is a novel, orally bioavailable, irreversible proteasome inhibitor with improved pharmacokinetics displaying preclinical efficacy with continuous daily dosing. | Cell Death Dis | 2015 |
| 24994712 | Immediate utility of two approved agents to target both the metabolic mevalonate pathway and its restorative feedback loop. | Cancer Res | 2014 |
| 23355037 | An integrin-targeted, pan-isoform, phosphoinositide-3 kinase inhibitor, SF1126, has activity against multiple myeloma in vivo. | Cancer Chemother Pharmacol | 2013 |
| 23968501 | Inhibiting aberrant signal transducer and activator of transcription protein activation with tetrapodal, small molecule Src homology 2 domain binders: promising agents against multiple myeloma. | J Med Chem | 2013 |
| 23810672 | A 2,6,9-hetero-trisubstituted purine inhibitor exhibits potent biological effects against multiple myeloma cells. | Bioorg Med Chem | 2013 |
| 21220410 | The tricyclic antidepressant amitriptyline inhibits D-cyclin transactivation and induces myeloma cell apoptosis by inhibiting histone deacetylases: in vitro and in silico evidence. | Mol Pharmacol | 2011 |
| 21788134 | Identification of a non-phosphorylated, cell permeable, small molecule ligand for the Stat3 SH2 domain. | Bioorg Med Chem Lett | 2011 |
| 21632854 | Molecular target characterization and antimyeloma activity of the novel, insulin-like growth factor 1 receptor inhibitor, GTx-134. | Clin Cancer Res | 2011 |
| 21618433 | Antagonism of the Stat3-Stat3 protein dimer with salicylic acid based small molecules. | ChemMedChem | 2011 |
| 21189385 | Single-agent lenalidomide in the treatment of previously untreated chronic lymphocytic leukemia. | J Clin Oncol | 2011 |
| 20360469 | Exploiting the mevalonate pathway to distinguish statin-sensitive multiple myeloma. | Blood | 2010 |
| 20505154 | Effect of noncompetitive proteasome inhibition on bortezomib resistance. | J Natl Cancer Inst | 2010 |
| 19805681 | Spontaneous remission in a patient with t(4;14) translocation multiple myeloma. | J Clin Oncol | 2009 |
| 19901323 | Multiple myeloma phosphotyrosine proteomic profile associated with FGFR3 expression, ligand activation, and drug inhibition. | Proc Natl Acad Sci U S A | 2009 |
| 18271526 | Tandem immunoprecipitation of phosphotyrosine-mass spectrometry (TIPY-MS) indicates C19ORF19 becomes tyrosine-phosphorylated and associated with activated epidermal growth factor receptor. | J Proteome Res | 2008 |
| 17255285 | The Bcl-2 family protein inhibitor, ABT-737, has substantial antimyeloma activity and shows synergistic effect with dexamethasone and melphalan. | Clin Cancer Res | 2007 |
| 17568814 | Diagnostic evaluation of t(4;14) in multiple myeloma and evidence for clonal evolution. | Leukemia | 2007 |
| 17332241 | Preclinical studies of the pan-Bcl inhibitor obatoclax (GX015-070) in multiple myeloma. | Blood | 2007 |
| 16467200 | The inhibitory anti-FGFR3 antibody, PRO-001, is cytotoxic to t(4;14) multiple myeloma cells. | Blood | 2006 |
| 16849642 | MIP-1alpha (CCL3) is a downstream target of FGFR3 and RAS-MAPK signaling in multiple myeloma. | Blood | 2006 |
| 15761022 | Immunohistochemistry accurately predicts FGFR3 aberrant expression and t(4;14) in multiple myeloma. | Blood | 2005 |
| 15598814 | CHIR-258, a novel, multitargeted tyrosine kinase inhibitor for the potential treatment of t(4;14) multiple myeloma. | Blood | 2005 |
| 15126369 | Soluble interleukin-13Ralpha2 decoy receptor inhibits Hodgkin's lymphoma growth in vitro and in vivo. | Cancer Res | 2004 |
| 15381729 | The SH3-SAM adaptor HACS1 is up-regulated in B cell activation signaling cascades. | J Exp Med | 2004 |
| 14871245 | Preclinical studies of fibroblast growth factor receptor 3 as a therapeutic target in multiple myeloma. | Br J Haematol | 2004 |
| 12907145 | RU486-inducible retrovirus-mediated caspase-3 overexpression is cytotoxic to bcl-xL-expressing myeloma cells in vitro and in vivo. | Mol Ther | 2003 |
| 14692533 | Improved therapeutic outcome following combination immunogene vaccination therapy in murine myeloma. | Leuk Lymphoma | 2003 |
| 14502228 | A phase I trial of adenovector-mediated delivery of interleukin-2 (AdIL-2) in high-risk localized prostate cancer. | Cancer Gene Ther | 2003 |
| 11999572 | Antigenic open reading frames from HHV-8 are present in multiple myeloma patients and normal individuals at similar frequency. | Leuk Lymphoma | 2002 |
| 12200383 | A molecular compendium of genes expressed in multiple myeloma. | Blood | 2002 |
| 12393593 | Overexpression of the myeloma-associated oncogene fibroblast growth factor receptor 3 confers dexamethasone resistance. | Blood | 2002 |
| 11477456 | Tricistronic viral vectors co-expressing interleukin-12 (1L-12) and CD80 (B7-1) for the immunotherapy of cancer: preclinical studies in myeloma. | Cancer Gene Ther | 2001 |
| 11368448 | Adenovector engineered interleukin-2 expressing autologous plasma cell vaccination after high-dose chemotherapy for multiple myeloma--a phase 1 study. | Leukemia | 2001 |
| 11290605 | The myeloma-associated oncogene fibroblast growth factor receptor 3 is transforming in hematopoietic cells. | Blood | 2001 |
| 10648414 | Ectopic expression of fibroblast growth factor receptor 3 promotes myeloma cell proliferation and prevents apoptosis. | Blood | 2000 |